mTOR inhibitors were also associated with significantly lower rates of HCC recurrence after liver transplantation when compared with CNIs (8% vs. 13.8%; p < 0.001) in a systematic review of 3666 HCC liver transplant recipients [47]. Here, MTOR is linked to hepatocellular carcinoma.